Analysis
Amgen has successfully mitigated the primary impacts of the April 2025 Tariff Executive Order (EO) through strategic industry exceptions and company-specific relief. While the EO imposed a universal 10% tariff on goods imported into the United States, pharmaceuticals were specifically listed as a category for exception, shielding the company's core product portfolio from direct duty costs. Management noted that their financial guidance for FY2025 already accounted for the estimated impact of all implemented tariffs, suggesting that any residual costs were manageable within their existing operating margin framework.
A significant component of Amgen's mitigation strategy involved securing specific relief from Section 232 tariffs, which typically target industrial materials such as steel and aluminum. In December 2025, the company received a three year reprieve from these duties in recognition of its substantial capital investments in U.S.-based manufacturing facilities. These investments include multi-billion dollar projects in Ohio, North Carolina, Rhode Island, and California. The relief effectively offsets potential cost increases for the construction and maintenance of these state-of-the-art facilities, which are critical for the production of upcoming pipeline launches like MariTide.
Despite these mitigations, the company remains vigilant regarding the broader trade environment. Management has clarified that while implemented tariffs are reflected in their outlook, their guidance does not account for potential future or "sector-specific" tariffs that have been proposed but not yet enacted. The company continues to prioritize a "double down" strategy on U.S. manufacturing as both an operational necessity and a policy buffer against future trade protection measures. This proactive stance, combined with the pharmaceutical industry's general exemption from the universal 10% tariff, has largely insulated Amgen from the severe financial headwinds associated with the 2025 tariff updates.
Data
| Event / Policy | Date | Nature of Impact | Mitigation / Relief Status |
|---|---|---|---|
| April 2025 Tariff EO | Apr-2025 | 10% Universal Import Tariff | Exception granted for pharmaceuticals |
| Section 232 Tariffs | Dec-2025 | Duties on industrial/manufacturing materials | Relief granted for 3 years due to U.S. investment |
| FY2025 Financial Impact | FY-2025 | General headwind (not quantified) | Included in company guidance |
| FY2026 Guidance | Feb-2026 | Potential future tariffs | Not included in $37.0B - $38.4B revenue range |
Source: Annual Report FY-2025, Transcript FY-2025, Marvin Labs
Sources
The April 2025 Tariff EO... imposed a universal 10% tariff on goods imported into the United States, with certain exceptions including pharmaceuticals.
In December 2025, in recognition of our capital investments in U.S. manufacturing, we received relief from Section 232 tariffs... for approximately the next three years.
This guidance includes the estimated impact of implemented tariffs. It does not account for tariffs or pricing actions announced or described, but not yet implemented.